trending Market Intelligence /marketintelligence/en/news-insights/trending/36iilPWRt5MWpUQmfa9Pkg2 content esgSubNav
In This List

US FDA clears Loxo Oncology's application for cancer drug

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


US FDA clears Loxo Oncology's application for cancer drug

The U.S. FDA cleared Loxo Oncology Inc.'s investigational new drug application for its next-generation tyrosine receptor kinase, or TRK, inhibitor, LOXO-195, to treat patients with TRK fusion cancers who become resistant while receiving another TRK inhibitor, such as larotrectinib.

Loxo plans to develop the product as a sequential treatment, to follow larotrectinib or another TRK inhibitor, to extend the total time of benefit from TRK inhibition.

The drug will initially be studied in a phase 1/2 trial, whose primary objective will be to determine the maximum tolerated dose or recommended dose for further study.